Supplementary Information for

Electrophysiological measures from iPSC-derived neurons are associated with schizophrenia and predict donor cognitive performance

Stephanie Cerceo Page^{1*}, Srinidhi Rao Sripathy^{1*}, Federica Farinelli^{1*}, Zengyou Ye^{1*}, Yanhong Wang^{1*}, Daniel J Hiler¹, Elizabeth A Pattie¹, Claudia V Nguyen¹, Madhavi Tippani¹, Rebecca L. Moses¹, Huei-Ying Chen¹, Matthew Nguyen Tran^{1,2}, Nicholas J Eagles¹, Joshua M Stolz¹, Joseph L Catallini II^{1,3}, Olivia R Soudry¹, Dwight Dickinson⁴, Karen F Berman⁴, Jose A Apud⁴, Daniel R Weinberger^{1,2,5,6,7}, Keri Martinowich^{1,5,6#}, Andrew E Jaffe^{1,3,5,6,8#}, Richard E Straub^{1#}, Brady J Maher^{1,5,6#†}

Brady J. Maher Brady.maher@libd.org

This PDF file includes:

Figures S1-S12 Index of Datasets S1 to S7

Other supplementary materials for this manuscript include the following:

Datasets S1 to S7



Fig. S1. No significant effect of diagnosis on hiPSC pluripotency. qPCR quantification of stem cell markers in **a**, *LIN28A* (CON=1.247 \pm 0.101, SCZ=1.225 \pm 0.092, p=0.87, N=35 from 28 genomes), **b**, *KLF4* (CON=0.418 \pm 0.045, SCZ=0.4805 \pm 0.051, p=0.37, N=35 from 28 genomes) and **c**, *OCT3/4* (CON=0.882 \pm 0.033, SCZ=0.924 \pm 0.055, p=0.51, N=35 from 28 genomes), all normalized to their expression in embryonic stem cell line H1.



Fig. S2. Neuron cell types generated are not different by diagnosis. a, Representative image from the same line (orchid), 70 days post-differentiation, DAPI (blue), NeuN (white), and cellular identity markers GAD67 (green) and tyrosine hydroxylase (TH, red), upper cortical layer markers SATB2 (green) and BRN2 (red), and deeper cortical layers markers CTIP2 (green) and TBR1 (red). b, Following each differentiation, lines from each cohort were assayed for neuronal identity markers using immunocytochemistry followed by high-content imaging. We observed no differences in cell type composition between SCZ and CON lines when quantification was performed by proportion (Marker+NeuN+/NeuN+ cells: GAD1 CON=0.0643 ± 0.015, N=26; SCZ=0.0561 ± 0.013, N=32, full linear model p=0.95; TH CON=0.089 ± 0.018, N=26; SCZ=0.091 ± 0.019, N=29, full linear model p=0.92; SATB2 CON=0.141 ± 0.039, N=27; SCZ=0.107 ± 0.021, N=33, full linear model p=0.003; BRN2 CON=0.192 ± 0.035, N=21; SCZ=0.196 ± 0.040, N=25, full linear model p=0.83; CTIP2 CON=0.182 ± 0.025, N=28; SCZ=0.135 ± 0.021, N=34, full linear model p=0.49; TBR1 CON=0.237 ± 0.042, N=28; SCZ=0.315 ± 0.048, N=34, full linear model p=0.43). c, Normalized gene expression at DIV 70 showed no differences between CON and SCZ lines. Gene expression was normalized to mean expression of CON: SLC6A1 (GAT1)(SCZ effect=0.98, p=0.94 N=26 across 11 genomes), TH (SCZ effect=0.89, p=0.78 N=27 across 11 genomes, SATB2 (SCZ effect=1.15, p=0.76, N=27 across 11 genomes), POU3F2 (BRN2) (SCZ effect=1.49, p=0.43, N=27 across 11 genomes), BCL11B (CTIP2) (SCZ effect=1.60, p=0.39, N=27 across 11 genomes), TBR1 (SCZ effect=1.11, p= 0.78, N=27 across 11 genomes).



Fig. S3. Summary data of immunocytochemistry of neuronal cell type and cortical layer markers for each line. a, Summary data by line for percentage of neurons by line. **b**, Summary data by line for percentage of BRN2+ neurons. **c**, Summary data by line for percentage of CTIP2+ neurons. **d**, Summary data by line for percentage of CUX1+ neurons. **e**, Summary data by line for percentage of SATB2+ neurons. **f**, Summary data by line for percentage of TBR1+ neurons. **g**, Summary data by line for percentage of GABAergic neurons. **h**, Summary data by line for percentage of TH+ neurons.



Fig. S4. RNA-seq validation of cell states. a, Top principal components of gene expression relate to developmental changes. Triangle = NPC, Circle = Neuron; Color = batch. b, Variance components analyses of gene expression across each gene (ie each box is the distribution of variance explained across all expressed genes) - developmental stage and genome strongly influence expression variation, while differentiation round or the individual performing the differentiation did not. c, We represented cellular heterogeneity as the first principal component of the 10 cell class fractions, which captured 84% of the cellular variance explained, where adult and fetal guiescent neuron RNA fractions were associated with increased maturity, and NPCs and endothelial RNA fractions were associated with decreased maturity. As expected, hiPSC RNA signature decreases over development. d, The RNA fraction associated with NPCs increases then decreases over development. e, We used RNA deconvolution to estimate the RNA fractions for multiple cell classes, and confirmed that our cells align with the fetalreplicating class during the hNPC stage. f, Neurons display the fetal-quiescent class during the post-mitotic neuronal stage. g, Principal component analysis (PCA) performed on the human gene expression levels generated in this manuscript (in red, "LIBD"), visualizing PC1 versus PC2, the largest two components of variation. Point shapes corresponding to cell state (iPSC, NPC, and neuron). Identically-processed public datasets (other point colors) were projected into this latent space (PC1 versus PC2) and overlaid in the plot. h, Boxplot demonstrating components of variation for PC1 and i, the RNA fraction corresponding to the adult neuron signature, with LIBD-Neuron showing the highest degree of maturation.



Fig. S5. Gene expression changes in hiPSC-derived neurons correlate across cell states. a, Differentially expressed genes with FDR<0.05. **b**, Representative GO terms from DEGs at p<0.005. **c**, Gene expression correlates across cell states. **d**, Differentially expressed genes in neurons are observed in NPCs. **e**, Genes that are differentially expressed in NPCs remain differentially expressed in neurons. **f**, Correlation between gene expression in hiPSC-derived neurons when compared to TWAS data from postmortem DLPFC. **g**, Differential expression in hiPSC-derived neurons compared to TWAS data.



Fig. S6. Physiological assessment of cortical neurons. a, Representative traces of regions of interest in a CONculture. **b**, Proportion of active ROIs are not significantly different between CON and SCZ at an early developmental stage (DIV42, SCZ effect= -0.0494, p=0.403, N=426 across 35 lines). **c**, Proportion of active ROIs are not significantly different at a later developmental stage (DIV63) between CON and SCZ(SCZ effect= -0.0381, p=0.542, N=419 across 35 lines). **d**, Spontaneous network activity was primarily driven by glutamatergic synaptic transmission as the application of glutamatergic inhibitors dI-AP5 (100μM) and DNQX (10μM) results in a 70.2% decrease in the percentage of active ROIs in both CON and SCZ lines (N=14 CON, 8 SCZ lines, p=2.15E-22). **e**, Representative traces of spontaneous excitatory postsynaptic currents. **f**, Frequency of sEPSCs are not significantly different between CON and SCZ (SCZ effect=-0.147, p=0.188, N=954 across 28 genomes). **g**, Amplitude of sEPSCs are not significantly different between CON and SCZ (SCZ effect=-0.147, p=0.188, N=954 across 28 genomes). **g**, Amplitude of sEPSCs are not significantly different between CON and SCZ (SCZ effect=0.294, p=0.408, N=806 across 28 genomes).



Fig. S7. Summary data of calcium imaging by diagnosis and by line. a, Proportion of active ROIs by line (circle DIV42, square DIV63). **b**, Summary data of events per ROI by diagnosis at DIV42 (SCZ effect= -0.0136, p=0.9414, N_{CON}=3902, N_{SCZ}=2927). **c**, Summary data of events per ROI by diagnosis at DIV63 (SCZ effect=-0.040, p=0.828 N_{CON}=3616, N_{SCZ}=2866) **d**, Summary data of synchronicity of events by diagnosis at DIV42 (SCZ effect=-0.00383, p=0.9428, N_{CON}=3902, N_{SCZ}=2927). **e**, Summary data of synchronicity by diagnosis at DIV63 (SCZ effect=-0.0165, p=0.761, N_{CON}=3616, N_{SCZ}=2866). **f**, Synchronicity by line. **g**, Number of events per ROI is reduced following application of DNQX (10µM) and dI-AP5 (100µM), (baseline: N=2842, 8.37 \pm 0.257, DNQX + AP5: N=739, 2.14 \pm 0.204, p=1.34E-6) **h**, Synchronicity of events is decreased following application of DNQX (10µM) and dI-AP5 (100µM), (baseline: N=177, 0.160 \pm 0.012, DNQX + AP5: N=38, 0.029 \pm 0.00489, p=3.7E-5).



Fig. S8. Neuronal maturation of membrane properties. a, Summary data by diagnosis showing membrane capacitance increases between DIV 56 (d0) and 70 (d1)(d1-d0 effect=0.799, p=0.003, N=1086), but is not different by diagnosis (Both timepoints SCZ effect=-0.043, p=0.878, N=1086; d0 SCZ effect=0.064, p=0.862, N=566 across 28 genomes; d1 SCZ effect=-0.182, p=0.666, N=520 across 28 genomes). b, Group data showing membrane resistance increases between DIV 57 (d0) and 70 (d1)(d1-d0 effect=-55.11, p=2.55E-05, N=1086), and is different by diagnosis (Both timepoints SCZ effect=29.41, p=0.026, N=1086; d0 SCZ effect=21.85, p=0.260, N=566 across 28 genomes; d1 SCZ effect=40.67, p=0.02, N=520 across 28 genomes). c, Summary data showing resting membrane potentials become more depolarized between DIV 57 (d0) and 70 (d1)(d1-d0 effect=-1.94, p=0.002, N=1086), but do not differ by diagnosis (Both timepoints SCZ effect=0.665, p=0.295, N=1082; d0 SCZ effect=-2.022, p=0.023, N=565 across 28 genomes; d1 SCZ effect=0.890, p=0.331, N=517 across 28 genomes). d, Membrane property measures by line.



Fig. S9. Summary data of number of Na⁺ peaks and sIPSC frequency and amplitude. a,

Summary data by diagnosis showing number of Na⁺ peaks for DIV 56 (d0) and 70 (d1)(Both timepoints SCZ effect=0.093, p=0.038, N=1074 across 28 genomes; d0 SCZ effect=0.043, p=0.492, N=560 across 28 genomes; d1 SCZ effect=0.146, p=0.018, N=514 across 28 genomes). **b**, Summary data of Na⁺ peak counts for each line. **c**, Summary data by diagnosis showing sIPSC frequency for DIV 56 (d0) and 70 (d1)(Both timepoints SCZ effect=0.097, p=1.11E-06, N=903 across 28 genomes; d0 SCZ effect=0.049, p=0.082, N=449 across 28 genomes; d1 SCZ effect=0.143, p=2.10E-07, N=454 across 28 genomes). **d**, Summary data of sIPSC frequency for each line. **e**, Summary data by diagnosis showing sIPSC amplitude for DIV 56 (d0) and 70 (d1)(Both timepoints SCZ effect=2.131, p=10.184, N=591 across 28 genomes; d0 SCZ effect=1.903, p=0.250, N=304 across 28 genomes; d1 SCZ effect=2.421, p=0.350, N=287 across 28 genomes). **f**, Summary data of sIPSC amplitude for each line.



Fig. S10. Physiological relevance of multiple Na⁺ peaks. a, Representative traces showing TTX blockade of Na⁺ currents in response to a voltage ramp. b, Group data showing TTX blockade of Na⁺ currents (peak 1 TTX effect=0.989, peak 2 TTX effect= 0.931, P_{anova}=0.015, N=3). c, The maximum number of action potential is correlated with the number of Na⁺ peaks (CON N=625, R=0.347, p=1.87E-18; SCZ N=461, R=0.362, p=2.44E-15). d, The amplitude of action potentials are correlated with the number of Na⁺ current peaks (CON N=625, R=0.34, p=1.78E-15; SCZ N=461, R=0.279, p=1.65E-08). e, The acceleration of the action potential upslope (dV/dT) is correlated with the number of Na⁺ peaks (CON N=625, R=0.226, p=2.23E-07; SCZ N=461, R=0.245, p=7.89E-07). f, The action potential threshold is negatively correlated with the number of Na⁺ peaks (CON N=625, R=0.226, p=2.026, p=2.00E-09).



Fig. S11. Summary data for Na * channel activation and inactivation by genome. a,

Normalized conductance versus voltage plots for 6 SCZ and 7 CON lines. **b**, Curves in (a) were fitted with a Boltzmann function and the V1/2 for each neuron is reported. **c**, Normalized inactivation versus voltage plots for 6 SCZ and 7 CON lines. **d**, Curves in (c) were fitted with a Boltzmann function and the V1/2 for inactivation for each neuron is reported. **e**, Proportion of current remaining from the first voltage step pulse after consecutive voltage step pulses (P2/P1, P3/P1, P4/P1) for each neuron is reported.



Fig. S12. Summary data of inter-spike intervals for action potentials by genome. a, Duration of the 2nd inter-spike interval for each neuron is reported. **b**, Duration of the last interspike interval for each neuron is reported. **c**, Duration of the minimum inter-spike interval for each neuron is reported.

а

Index of Datasets S1-S7

Dataset S1 – Subjects, Cell Lines and Datasets

Dataset S2 – Association between electrophysiological measures and diagnosis

Dataset S3 – Correlation between electrophysiological measures and clinical symptoms or cognition in SCZ

Dataset S4 – Correlation between electrophysiological measures and clinical symptoms or cognition in CON

Dataset S5 – Linear regression: electrophysiological measures and clinical symptoms or cognition in [SCZ + CON]

Dataset S6 – Differential Gene Expression Results from Neural Progenitors Cells (NPCs)

Dataset S7 – Differential Gene Expression Results from Neurons